Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Asset Writedowns and Impairment (2016 - 2026)

Champions Oncology (CSBR) has 7 years of Asset Writedowns and Impairment data on record, last reported at $13000.0 in Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 106.22% year-over-year to $13000.0; the TTM value through Oct 2025 reached -$8000.0, up 78.95%, while the annual FY2025 figure was -$272000.0, 157.14% down from the prior year.
  • Asset Writedowns and Impairment reached $13000.0 in Q4 2025 per CSBR's latest filing, up from -$29000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $724000.0 in Q2 2023 and bottomed at -$209000.0 in Q4 2024.
  • Average Asset Writedowns and Impairment over 4 years is $76538.5, with a median of $48000.0 recorded in 2025.
  • The widest YoY moves for Asset Writedowns and Impairment: up 270.21% in 2024, down 390.28% in 2024.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $130000.0 in 2022, then tumbled by 44.62% to $72000.0 in 2023, then tumbled by 390.28% to -$209000.0 in 2024, then surged by 106.22% to $13000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $13000.0 in Q4 2025, -$29000.0 in Q3 2025, and $48000.0 in Q2 2025.